Drug reference
empagliflozin-linagliptin
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Drug class
Endocrine (Peptide analogues)
Mechanism of action
Empagliflozin: SGLT2 inhibitor; SGLT2 is expressed in the proximal renal tubules and is responsible for the majority of the reabsorption of filtered glucose from the tubular lumen. Linagliptin: DPP-4 inhibitor; increases and prolongs incretin hormone activity, which is inactivated by DPP-4 enzyme.
Common side effects
- Nasopharyngitis
- Hypoglycemia
- Increased LDL-C
- Increased hematocrit
- Ketoacidosis
- Urinary tract infection
Related conditions
Frequently asked questions
What drug class is empagliflozin-linagliptin?
empagliflozin-linagliptin belongs to: Endocrine.
How does empagliflozin-linagliptin work?
Empagliflozin: SGLT2 inhibitor; SGLT2 is expressed in the proximal renal tubules and is responsible for the majority of the reabsorption of filtered glucose from the tubular lumen. Linagliptin: DPP-4 inhibitor; increases and prolongs incretin hormone activity, which is inactivated by DPP-4 enzyme.
What are the common side effects of empagliflozin-linagliptin?
Nasopharyngitis, Hypoglycemia, Increased LDL-C, Increased hematocrit, Ketoacidosis, Urinary tract infection
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.